NRIX

Nurix Therapeutics, Inc. (NRIX) | Rumor.io

Nurix Therapeutics

NRIX

Attention (50-day avg)0%

Attention rank (50-day avg)#2,147

Bullish sentiment (50-day avg)60%

Price to earnings ratio-7.76

Market capitalization2.5B

Earnings per share-3.46

Dividend yield (TTM)—

Revenue (annual)84M

Net income (annual)-264.5M

Social

What share of all stock conversation is about NRIX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Jun 27

$NRIX experienced a 35% increase in value after a quant volumetric engine identified a potential buying opportunity.
The engine's analysis was based on a consolidation chart and two distinct footprints found on June 8-9.
The engine's method involves mapping institutional volume nodes to predict liquidity shifts.

Generated by AI

Sentiment

Of the messages about NRIX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +39.02	90.73% +1.55
Bearish	—	—	0% -39.02	9.27% -1.55

Bullish· Jun 9

$NRIX has received a significant partnership with Roche, with a $700M upfront payment and up to $2.3B in milestones, providing non-dilutive cash to fund its pipeline.
The company's deal with Roche is a major validation of its oral BTK degrader, and its 50/50 US profit split is a key benefit of the partnership.
Analysts are bullish on $NRIX, with multiple firms raising their price targets to $25-$45, driven by the Roche partnership and its potential to trade in the $30-$35 range over the next 12 months.

Bearish· Jun 8

The company's cash runway may be limited, with some estimates suggesting it could be as short as 3 years.
The stock's recent drop may be due to a "slow burner" perception, with some traders viewing it as a less exciting investment opportunity.
The company's funding and deal economics, including the upfront payment from Roche, are a key focus for investors, with some analysts expressing concerns about the potential for dilution.

Generated by AI

Topics

Of the messages about NRIX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	97.78%	88.25%
Technical Analysis	0%	0%	2.22%	5.25%
Analysts	0%	0%	0%	5.75%
Macro	0%	0%	0%	0.75%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%

Jun 8

Nurix Therapeutics has entered into a global collaboration with Roche to co-develop and co-commercialize the potential best-in-class BTK degrader bexobrutideg across malignant hematology, immunology, and neurology indications.
The deal is worth up to $2.3 billion, with Nurix receiving a $700 million upfront payment and eligible for additional milestone payments.
The collaboration will share development costs, and Roche will commercialize the drug outside the US, while Nurix will commercialize it in the US.

Generated by AI

Community

Of the messages about NRIX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	75%	88%	55.07%
Newcomers	0%	25%	12%	44.93%

Regulars· Jun 8

The collaboration between $NRIX and $RHHBY (Roche) has resulted in a $700 million upfront payment and a global deal to co-develop and co-commercialize bexobrutideg across malignant hematology, immunology, and neurology.
The deal is expected to establish Roche as a broad alliance partner for Nurix, with a significant upfront payment and the potential for future milestones, making Nurix an attractive acquisition target.
The partnership and subsequent price target updates from Jefferies ($45.00) and Truist Financial ($32.00) suggest a strong market interest in Nurix's future prospects, with the company's share price reacting positively to the news.

Newcomers· Jun 27

The newcomer's quant engine detected two distinct footprints on June 8-9, which were supported by a tight consolidation chart.
The stock has seen a significant gain of +35% since then, indicating a potential increase in investor interest.
The newcomer's tool maps institutional volume nodes to identify liquidity shifts, suggesting an approach to analyzing market dynamics.

Generated by AI

News

Here's Why You Should Add NRIX Stock to Your Portfolio Now

Nurix is developing bexobrutideg in CLL, while Roche's $2.3B deal and new studies support its potential in cancer, immunology and neurology.

20d agoYahoo Finance

Nurix Therapeutics (NRIX) Upgraded to Buy: Here's Why

20d agoYahoo Finance

Nurix Therapeutics at Wells Fargo conference: pipeline, deal momentum

21d agoInvesting.com

Also Discussed

Investors talking about NRIX also mention

#	Name	Attention
1	Kymera Therapeutics Inc.KYMR	0%0
2	Relay Therapeutics Inc.RLAY	0%new
3	Arcus Biosciences, Inc.RCUS	0%new
4	Spyre Therapeutics, Inc.SYRE	0%new
5	Cullinan Therapeutics Inc.CGEM	0%new
6	Kulicke & Soffa Industries, Inc.KLIC	0%0
7	Revolution Medicines, Inc.RVMD	0.01%-0.01
8	Lexicon Pharmaceuticals, Inc.LXRX	0%0
9	UFP Technologies Inc.UFPT	0%0
10	10x Genomics Inc. Class A Common StockTXG	0%-0.02

Nurix Therapeutics, Inc.

Healthcare
Biotechnology

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted protein degradation medicines. Nurix Therapeutics develops small-molecule and antibody-based therapies designed to modulate cellular protein levels through the ubiquitin-proteasome system, with applications in oncology, immunology, and inflammatory diseases. Its current pipeline includes investigational programs aimed at B-cell malignancies, immune-mediated disorders, and other serious conditions, supported by its DELigase discovery platform and expertise in E3 ligases. The company also advances partnered research and development programs with major pharmaceutical collaborators, combining internal drug discovery capabilities with broader development and commercialization efforts. Headquartered in San Francisco, California, Nurix Therapeutics plays a specialized role in the biotechnology market by translating protein degradation science into potential therapeutic candidates for diseases with limited treatment options.

Website

Location

1600 Sierra Point Parkway

Brisbane, CA, 94005

United States

Social

What share of all stock conversation is about NRIX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Jun 27

$NRIX experienced a 35% increase in value after a quant volumetric engine identified a potential buying opportunity.
The engine's analysis was based on a consolidation chart and two distinct footprints found on June 8-9.
The engine's method involves mapping institutional volume nodes to predict liquidity shifts.

Generated by AI

Sentiment

Of the messages about NRIX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +39.02	90.73% +1.55
Bearish	—	—	0% -39.02	9.27% -1.55

Bullish· Jun 9

$NRIX has received a significant partnership with Roche, with a $700M upfront payment and up to $2.3B in milestones, providing non-dilutive cash to fund its pipeline.
The company's deal with Roche is a major validation of its oral BTK degrader, and its 50/50 US profit split is a key benefit of the partnership.
Analysts are bullish on $NRIX, with multiple firms raising their price targets to $25-$45, driven by the Roche partnership and its potential to trade in the $30-$35 range over the next 12 months.

Bearish· Jun 8

The company's cash runway may be limited, with some estimates suggesting it could be as short as 3 years.
The stock's recent drop may be due to a "slow burner" perception, with some traders viewing it as a less exciting investment opportunity.
The company's funding and deal economics, including the upfront payment from Roche, are a key focus for investors, with some analysts expressing concerns about the potential for dilution.

Generated by AI

Topics

Of the messages about NRIX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	97.78%	88.25%
Technical Analysis	0%	0%	2.22%	5.25%
Analysts	0%	0%	0%	5.75%
Macro	0%	0%	0%	0.75%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%

Jun 8

Nurix Therapeutics has entered into a global collaboration with Roche to co-develop and co-commercialize the potential best-in-class BTK degrader bexobrutideg across malignant hematology, immunology, and neurology indications.
The deal is worth up to $2.3 billion, with Nurix receiving a $700 million upfront payment and eligible for additional milestone payments.
The collaboration will share development costs, and Roche will commercialize the drug outside the US, while Nurix will commercialize it in the US.

Generated by AI

Community

Of the messages about NRIX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	75%	88%	55.07%
Newcomers	0%	25%	12%	44.93%

Regulars· Jun 8

The collaboration between $NRIX and $RHHBY (Roche) has resulted in a $700 million upfront payment and a global deal to co-develop and co-commercialize bexobrutideg across malignant hematology, immunology, and neurology.
The deal is expected to establish Roche as a broad alliance partner for Nurix, with a significant upfront payment and the potential for future milestones, making Nurix an attractive acquisition target.
The partnership and subsequent price target updates from Jefferies ($45.00) and Truist Financial ($32.00) suggest a strong market interest in Nurix's future prospects, with the company's share price reacting positively to the news.

Newcomers· Jun 27

The newcomer's quant engine detected two distinct footprints on June 8-9, which were supported by a tight consolidation chart.
The stock has seen a significant gain of +35% since then, indicating a potential increase in investor interest.
The newcomer's tool maps institutional volume nodes to identify liquidity shifts, suggesting an approach to analyzing market dynamics.

Generated by AI

Nurix Therapeutics

Social

Jun 27

Bullish· Jun 9

Bearish· Jun 8

Jun 8

Regulars· Jun 8

Newcomers· Jun 27

Nurix receives $7m milestone payment from Pfizer collaboration

Nurix at Morgan Stanley healthcare conference: roche deal drives growth

Nurix at H.C. Wainwright conference: Roche deal lifts outlook

Here's Why You Should Add NRIX Stock to Your Portfolio Now

Nurix Therapeutics (NRIX) Upgraded to Buy: Here's Why

Nurix Therapeutics at Wells Fargo conference: pipeline, deal momentum

Also Discussed

Nurix Therapeutics, Inc.

Company Information

Location

Nurix receives $7m milestone payment from Pfizer collaboration

Nurix at Morgan Stanley healthcare conference: roche deal drives growth

Nurix at H.C. Wainwright conference: Roche deal lifts outlook

Here's Why You Should Add NRIX Stock to Your Portfolio Now

Nurix Therapeutics (NRIX) Upgraded to Buy: Here's Why

Nurix Therapeutics at Wells Fargo conference: pipeline, deal momentum

Also Discussed

Social

Jun 27

Bullish· Jun 9

Bearish· Jun 8

Jun 8

Regulars· Jun 8

Newcomers· Jun 27